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REPLY
We agree with Dr. Standing that a pediatric formulation of
bosentan is needed. The pharmaceutical development of a pediat-
ric formulation, in the form of an orodispersible tablet with a
flexible dosage of 8 to 32 mg, is currently undergoing clinical
evaluation in children in Europe and in the U.S.
However, during the course of development and validation of
the pediatric formulation, the current adult formulation of bosen-
tan was used to begin evaluation of the pharmacokinetics and
safety of bosentan in children (1). We acknowledge that we do not
describe in detail in our study (2) the technical aspects associated
with cutting the adult tablets for the treatment of children.
However, several studies have shown the adult formulation is
suitable to this situation:
1. The active bosentan substance is uniformly spread throughout
the bosentan tablet.
2. Seventy-five percent of the tablet weight is drug substance,
thereby limiting the possibility of nonuniformity of the med-
ication dose.
3. The weight of halved tablets, split with a commercially
available tablet cutter, was within European and U.S. Phar-
macopeia specifications (Actelion, personal communication,
2001). In addition, dissolution rates were measured and found
to be similar for both whole and halved tablets.
Therefore, the use of split tablets was considered appropriate for
conducting a pharmacokinetic study (1). Quartered tablets were
not tested at that time. In our study (2), we followed the sponsor’s
recommendations of using a commercially available cutter to split
the tablets, with no crushing of halved/quartered tablets, and direct
oral administration.
Whereas the pharmaceutical development of the pediatric
formulation of bosentan was ongoing, we treated children with
symptomatic pulmonary arterial hypertension (PAH) at our clinics
with the adult bosentan formulation following the sponsor’s
recommendation for dosing in children at that time (i.e., based on
a conservative extrapolation by weight of the recommended adult
dosages). Using this approach, these data demonstrated the safety
and efficacy of bosentan for pediatric PAH. However, we also
agree with Dr. Standing that pediatric dosing needs to be studied
further. We anticipate that the current evaluation of a pediatric
bosentan formulation will lead to optimal bosentan dosing regi-
mens for children with PAH.
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Limitations of Crush Technique
Ge et al. (1) reported the results of a prospective study on long-term
outcomes of “crush technique” (CT) with drug-eluting stents. This
study raises, in our opinion, two main issues.
First, as pointed out by Williams and Abbott in their editorial
(2), this study reports a clearly worse outcome as compared to
studies with “provisional T stenting” (PTS) and serious concerns
about safety profile (4.4% incidence of stent thrombosis). More-
over, the success rate in recrossing the stent struts for final kissing
balloon is not reported in the study. Because 36% of patients did
not undergo final kissing balloon postdilation, we may assume that,
at least in some of them, it was not possible to recross the stent
struts. This is an important limitation as any further therapy of
side-branch restenosis in “unrecrossable” patients (40% incidence)
becomes virtually impossible by means of percutaneous coronary
intervention (PCI). From this perspective, PTS appears also to be
superior as a second stent is needed in only 15% to 33% of cases,
and final kissing balloon is possible in 95% of cases (3).
Additionally, in case of side-branch restenosis it is always possible
to perform additional PCI. Taken together these limitations may
“crush” down the clinical role of CT, a conclusion not clearly
underlined by the investigators.
Second, the modest results of CT reported in the study by Ge
et al. (1) are not surprising. In fact, CT results in three drug-
eluting stent (DES) layers crushed on an arterial wall at a site of
high hemodynamic turbulence, with high chances of the stents’
incomplete expansion where the coverage should be maximal. This
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is likely to bring high restenosis incidence and strong local
thrombogenic stimuli. Therefore, based on previous studies, a
pre-hoc possibility of important adverse events was predictable.
Aswidely accepted, off-label and potentially harmful techniques
should be used with great caution, selecting patients on an
individual basis and informing them of the experimental nature of
the technique. The study does not report whether a clinical
selection of patients was performed or whether an approval from
the local ethics committee and a specific informed consent were
obtained. It is our strong belief that conduction of a study on a new
therapeutic off-label technique with potentially severe concerns
should bear the same obligations as all other studies investigating
new drugs, devices, or a new indication for them. Therefore, a
research-oriented informed consent from the patients and an
ethical committee approval should be mandatory and clearly stated
in reports relating to these subjects.
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REPLY
We thank Dr. Pristipino and colleagues for their interesting
comments about our report. The opportunity to answer their
comments will allow clarification of some concerns regarding this
innovative approach.
Worse outcome compared to provisional T stenting (PTS). Our
report of the crush stenting experience is not meant to be directly
compared to the PTS as already reported by us (1). A number of
bifurcations with severe narrowing occur in both branches where
PTS is not conceivable as an intention-to-treat approach; the crush
technique is specifically designed for these types of lesions. It is
always misleading to try to compare different studies performed on
different types of bifurcations with a variety of different inclusion
criteria. We recognize that there is no substitute for appropriately
designed prospective randomized studies. This is the main reason
why we launched the Coronary bifurcations: Application of the
Crushing Technique Using Sirolimus-eluting stents (CACTUS)
trial, which prospectively evaluated the PTS technique versus the
crush technique (CT) in true bifurcational lesions.
Incidence of stent thrombosis of 4.4% with the CT. A 4.4%
incidence in 181 patients bears a 95% confidence interval of 2.3%
to 8.5%. In addition, it is important to point out that in
threepatients the thrombosis was intraprocedural and possibly
related to suboptimal anticoagulant or antiplatelet therapy,
whereas two other events occurred in a patient who prematurely
stopped antiplatelet therapy.
Very recently, we reported a 3.6% rate of cumulative stent
thrombosis after drug-eluting stent (DES) implantation in bifur-
cations in a prospective observational cohort study that included
2,229 patients treated with DESs (2). In this study, bifurcation
lesion treatment was identified as an independent predictor of
subacute (postprocedure to 30 days), late (30 days), and cumu-
lative thrombosis. However, no significant differences existed
regarding the incidence of thrombosis in bifurcations treated with
one versus two stents.
Kissing balloon inflation and success in recrossing. In our initial
experience with the CT we did not believe that recrossing into the
side branch so as to perform kissing balloon inflation was a
mandatory step. We performed kissing balloon inflation in about
one-third of cases when the angiographic result was not optimal.
The relatively high angiographic restenosis prompted us to always
recross into the side branch and perform final kissing inflation.
Our success in recrossing into the side branch in the experience
reported was 100% and continues to remain high. Availability of
improved wires and low-profile balloons makes recrossing into the
side branch and performance of balloon inflations a step that adds
only a few minutes to the procedure.
The modest results . . . and the three layers of struts. Ever since the
institution of routine high-pressure inflation into the side branch
and kissing balloon inflation, as reported in the study, we saw an
angiographic restenosis in the side branch of 11.1%, and in
many instances focal restenosis at the ostium of the side branch
is not clinically relevant. The problem of multiple layers of
struts appears more theoretical than practical owing to the fact
that the struts’ overlap is limited to 1 or 2 mm. Intravascular
ultrasound studies did not demonstrate any lumen compromise at
the level of the overlap in the main branch, and the real issue is
frequently an incomplete expansion of the lesion at the ostium of
the side branch (3).
Usage of off-label technique. We fully agree that any usage of a
device for an unlabeled indication must be very carefully performed
after having evaluated alternative solutions. The field of invasive
cardiology is full of situations in which devices are used outside the
labeling instructions; these responsible decisions allow treatment of
many patients who would otherwise receive a suboptimal therapy.
Careful off-label usage is essential to give initial information to
plan prospective studies designed to demonstrate safety and effi-
cacy. Coronary stenting in acute myocardial infarction is a typical
example of this path. The results we reported were obtained from
analyzing stenting in bifurcational lesions using the optimal
technique according to the operator. This experience was not a
predesigned study to compare different techniques. This type of
evaluation does not require a dedicated consent form in addition to
the one for the procedure being done. Using feedback from many
other operators, the CT, if applied to the appropriate bifurcations
and if properly performed, remains a valuable tool to treat
bifurcational lesions. Of course, we hope that dedicated stents
specifically designed for this lesion subset may further improve the
results in this important area of interventional cardiology.
1916 Correspondence JACC Vol. 47, No. 9, 2006
May 2, 2006:1904–17
